HCAR2 and Huntington disease: If HCAR2 is indeed a major therapeutic target of DMF in AD, PD, and HD, then the ketone body ß-hydroxybutyrate, a known HCAR2 ligand, may prove to be a more suitable therapeutic than DMF, MEF, or MMF43,44.